Neo Ivy Capital Management Sells 18,687 Shares of Halozyme Therapeutics, Inc. $HALO

Neo Ivy Capital Management cut its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 77.6% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 5,386 shares of the biopharmaceutical company’s stock after selling 18,687 shares during the quarter. Neo Ivy Capital Management’s holdings in Halozyme Therapeutics were worth $395,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Root Financial Partners LLC bought a new stake in Halozyme Therapeutics during the 3rd quarter worth about $25,000. Richardson Financial Services Inc. lifted its position in shares of Halozyme Therapeutics by 87.6% during the third quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 198 shares in the last quarter. Newbridge Financial Services Group Inc. bought a new stake in shares of Halozyme Therapeutics during the second quarter valued at approximately $32,000. Employees Retirement System of Texas acquired a new stake in shares of Halozyme Therapeutics in the second quarter valued at approximately $34,000. Finally, Clearstead Advisors LLC raised its position in Halozyme Therapeutics by 107.7% in the 3rd quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 265 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Transactions at Halozyme Therapeutics

In related news, Director Bernadette Connaughton sold 2,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $70.25, for a total value of $140,500.00. Following the sale, the director owned 40,123 shares of the company’s stock, valued at approximately $2,818,640.75. This trade represents a 4.75% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $76.12, for a total value of $1,522,400.00. Following the completion of the sale, the chief executive officer owned 708,719 shares in the company, valued at $53,947,690.28. The trade was a 2.74% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 62,000 shares of company stock valued at $4,545,200. 2.90% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

HALO has been the topic of several research reports. Benchmark upped their price objective on Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, February 19th. TD Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th. The Goldman Sachs Group reissued a “sell” rating and set a $56.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, December 4th. Wall Street Zen lowered shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Saturday, February 21st. Finally, Weiss Ratings cut shares of Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research report on Tuesday, February 24th. Six research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $78.56.

Halozyme Therapeutics Trading Up 0.0%

NASDAQ HALO opened at $67.37 on Monday. Halozyme Therapeutics, Inc. has a 12 month low of $47.50 and a 12 month high of $82.22. The stock has a 50-day simple moving average of $72.66 and a 200 day simple moving average of $70.72. The company has a current ratio of 4.66, a quick ratio of 3.66 and a debt-to-equity ratio of 43.89. The company has a market capitalization of $7.95 billion, a PE ratio of 27.06, a P/E/G ratio of 0.27 and a beta of 0.98.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.92 by ($2.16). Halozyme Therapeutics had a return on equity of 136.12% and a net margin of 22.69%.The company had revenue of $451.77 million for the quarter, compared to the consensus estimate of $446.13 million. During the same quarter last year, the business posted $1.26 EPS. Halozyme Therapeutics’s quarterly revenue was up 51.6% on a year-over-year basis. Research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.